Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alnuctamab
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Alnuctamab is a bispecific monoclonal antibody designed as a T-cell engager for the treatment of relapsed and/or refractory multiple myeloma. It targets both the B-cell maturation antigen (BCMA; TNFRSF17) on malignant plasma cells and CD3 on T cells, facilitating T cell-mediated cytotoxicity against BCMA-expressing myeloma cells[1][4][5][6]. Alnuctamab has demonstrated antitumor activity in preclinical and early clinical studies, with ongoing trials evaluating its safety and efficacy in patients who have failed prior therapies[4][6][7]. The drug was originally developed by EngMab and further developed by Celgene Corporation, now part of Bristol Myers Squibb[5]. Clinical development has included both intravenous and subcutaneous formulations, with subcutaneous administration showing improved safety profiles regarding cytokine release syndrome (CRS)[4].
- Other names
- alnuctamab
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on alnuctamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alnuctamab.